News
11-04-2015, 02:41 AM
OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $7.5 million of securities in a registered direct offering.
More... (http://www.news-medical.net/news/20151104/OncoSec-signs-definitive-agreements-to-purchase-2475-million-of-securities-in-registered-direct-offering.aspx)
More... (http://www.news-medical.net/news/20151104/OncoSec-signs-definitive-agreements-to-purchase-2475-million-of-securities-in-registered-direct-offering.aspx)